Advertisement
FOCL vs HBIO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FOCL is a Buy and HBIO is a StrongBuy.
FOCL in +1.93% Uptrend, advancing for three consecutive days on October 26, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where FOCL advanced for three days, in 185 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 41 of 56 cases where FOCL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on FOCL as a result. In 67 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for FOCL just turned positive on October 21, 2026. Looking at past instances where FOCL's MACD turned positive, the stock continued to rise in 31 of 41 cases over the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
FOCL moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for FOCL moved below the 200-day moving average on October 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FOCL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for FOCL entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. FOCL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: FOCL's P/B Ratio (-61.199) is slightly lower than the industry average of (12.781). P/E Ratio (-4.019) is within average values for comparable stocks, (10.435). FOCL's Projected Growth (PEG Ratio) (8.100) is very high in comparison to the industry average of (2.016). Dividend Yield (0.000) settles around the average of (0.139) among similar stocks. P/S Ratio (1.919) is also within normal values, averaging (4.260).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FOCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock worse than average.
Momentum Indicator for HBIO turns positive, indicating new upward trend
HBIO saw its Momentum Indicator move above the 0 level on October 26, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 101 similar instances where the indicator turned positive. In 76 of the 101 cases, the stock moved higher in the following days. The odds of a move higher are at 75%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for HBIO just turned positive on October 29, 2026. Looking at past instances where HBIO's MACD turned positive, the stock continued to rise in 39 of 52 cases over the following month. The odds of a continued upward trend are 75%.
Following a +5.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where HBIO advanced for three days, in 159 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
HBIO broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. HBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 87 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.462) is normal, around the industry mean (4.913). P/E Ratio (-3.870) is within average values for comparable stocks, (38.128). HBIO's Projected Growth (PEG Ratio) (14.400) is slightly higher than the industry average of (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.410) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
FOCL | HBIO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 46 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 52 Fair valued | 97 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 42 | 36 | |
P/E GROWTH RATING 1..100 | 19 | 87 | |
SEASONALITY SCORE 1..100 | 50 | 49 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
FOCL's Valuation (52) in the Biotechnology industry is somewhat better than the same rating for HBIO (97). This means that FOCL’s stock grew somewhat faster than HBIO’s over the last 12 months.
FOCL's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as HBIO (100). This means that FOCL’s stock grew similarly to HBIO’s over the last 12 months.
HBIO's SMR Rating (98) in the Biotechnology industry is in the same range as FOCL (100). This means that HBIO’s stock grew similarly to FOCL’s over the last 12 months.
HBIO's Price Growth Rating (36) in the Biotechnology industry is in the same range as FOCL (42). This means that HBIO’s stock grew similarly to FOCL’s over the last 12 months.
FOCL's P/E Growth Rating (19) in the Biotechnology industry is significantly better than the same rating for HBIO (87). This means that FOCL’s stock grew significantly faster than HBIO’s over the last 12 months.
| FOCL | HBIO | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 76% |
| Stochastic ODDS (%) | 2 days ago 73% | 1 day ago 85% |
| Momentum ODDS (%) | 2 days ago 74% | 1 day ago 75% |
| MACD ODDS (%) | 2 days ago 76% | 1 day ago 75% |
| TrendWeek ODDS (%) | 2 days ago 77% | 1 day ago 78% |
| TrendMonth ODDS (%) | 2 days ago 85% | 1 day ago 78% |
| Advances ODDS (%) | 5 days ago 76% | 1 day ago 72% |
| Declines ODDS (%) | 12 days ago 84% | 8 days ago 87% |
| BollingerBands ODDS (%) | N/A | 1 day ago 86% |
| Aroon ODDS (%) | 2 days ago 90% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
FOCL’s FA Score shows that 1 FA rating(s) are green while HBIO’s FA Score has 0 green FA rating(s).
- FOCL’s FA Score: 1 green, 4 red.
- HBIO’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
FOCL’s TA Score shows that 4 TA indicator(s) are bullish while HBIO’s TA Score has 3 bullish TA indicator(s).
- FOCL’s TA Score: 4 bullish, 4 bearish.
- HBIO’s TA Score: 3 bullish, 4 bearish.
Price Growth
FOCL (@Medical Distributors) experienced а +0.24% price change this week, while HBIO (@Pharmaceuticals: Other) price change was +8.14% for the same time period.
The average weekly price growth across all stocks in the @Medical Distributors industry was +1.68%. For the same industry, the average monthly price growth was -7.47%, and the average quarterly price growth was -23.70%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.77%. For the same industry, the average monthly price growth was -3.29%, and the average quarterly price growth was +8.60%.
Reported Earning Dates
FOCL is expected to report earnings on Nov 05, 2026.
HBIO is expected to report earnings on Nov 10, 2026.
Industries' Descriptions
@Medical Distributors (+1.68% weekly)Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
@Pharmaceuticals: Other (-1.77% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
FOCL and
Correlation & Price change
A.I.dvisor tells us that FOCL and AORT have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that FOCL and AORT's prices will move in lockstep.
| Ticker / NAME | Correlation To FOCL | 1D Price Change % | ||
|---|---|---|---|---|
| FOCL | 100% | +0.24% | ||
| AORT - FOCL | 29% Poorly correlated | -3.67% | ||
| UFPT - FOCL | 20% Poorly correlated | -3.00% | ||
| SENS - FOCL | 20% Poorly correlated | -2.46% | ||
| STXS - FOCL | 16% Poorly correlated | -5.21% | ||
| HBIO - FOCL | 11% Poorly correlated | +1.14% | ||
More | ||||